The purpose of this study is to better understand the mode of action of digitoxin (or digoxin or derivatives) in breast cancer cells, particularly its interaction with doxorubicin, to determine its potential as a therapeutic agent. The utility lies in its ability to target HER2-overexpressing and ER-low breast cancer cells by modulating key genetic pathways and enhancing the efficacy of doxorubicin. This approach could lead to more effective treatments for certain types of breast cancer, particularly ER-negative cancers that are difficult to treat with existing therapies.
For more information or to license this innovation:
- Log In
to view the innovation's details
- Sign Up
with discount code "ECOS"
